Listen Now
Topics Covered
- Definition of Diagnostic Technologies for People Living with Solid Cancer Tumors, in the Context of COVID-19
- How Diagnostic Technologies Work & Are Used
- Examples of How Diagnostic Technologies Inform/Transform the Treatment of Solid Cancer Tumors
- Predicting Hereditary Risk
- Diagnostic Technologies, Targeted Therapies & Precision Medicine
- Clinical Trial Updates, in the Context of COVID-19
- Their Benefits
- Current Application for People Living with Solid Cancer Tumors
- The Increasing Role of Telehealth/Telemedicine Appointments, in the Context of COVID-19
- Questions for Our Panel of Experts
Our Panel of Experts

Mark G. Kris, MD
William and Joy Ruane Chair in Thoracic Oncology, Attending Physician, Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College

Al B. Benson, III, MD, FACP, FACCC, FASCO
Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Kamel Abou Hussein, MD
Lead Physician, Breast Medical Oncology, MD Anderson at Cooper Cancer Center

Sarah E. Kerr, MD
Pathologist, Hospital Pathology Associates, P.A., Divisions of Cytopathology; Gynecologic and Perinatal Pathology; Molecular Diagnostic Lead Pathologist for Next Generation Sequencing Development and Practice, Allina Health Laboratory (A Part of Abbott Northwestern Hospital)

Sarah Thibault-Sennett, PhD
Senior Manager, Public Policy & Advocacy, Association for Molecular Pathology (AMP)

Carolyn Messner, DSW, BCD, FAPOS, FAOSW
Director of Education and Training, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on May 17, 2021.